AssetMark Inc
FULC icon

AssetMark Inc’s Fulcrum Therapeutics FULC Stock Holding History

AssetMark Inc’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$21.6K Sell
5,833
-1,488
-20% -$5.58K ﹤0.01% 2223
2026
Q2 		$26.8K Sell
7,321
-204
-3% -$1.24K ﹤0.01% 2076
2026
Q1 		$57.7K Sell
7,525
-659
-8% -$6.11K ﹤0.01% 1708
2025
Q4 		$92.6K Sell
8,184
-1,427
-15% -$14.5K ﹤0.01% 1521
2025
Q3 		$88.4K Buy
+9,611
New +$69.5K ﹤0.01% 1467

Other funds holding FULC

GSK plc
GSK plc London $497M AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Peapod Lane Capital
Peapod Lane Capital Bedford Hills, New York $134M AUM 63.91% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Simplify Asset Management
Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

AssetMark Inc's FULC Position: Q3 2026 in Review

AssetMark Inc reduced its Fulcrum Therapeutics (FULC) stake by 20% in Q3 2026, selling an estimated $5.58K and leaving 5,833 shares worth $21.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2223.

AssetMark Inc first reported a position in FULC in Q3 2025 and has held it in 5 quarters since. The position peaked at $92.6K in Q4 2025. 42 funds tracked by Wall St. Rank hold FULC as of Q3 2026.

  • AssetMark Inc held 5,833 shares of Fulcrum Therapeutics worth $21.6K as of Q3 2026.
  • AssetMark Inc sold 1,488 Fulcrum Therapeutics shares in Q3 2026, an estimated $5.58K.
  • Fulcrum Therapeutics made up ﹤0.01% of AssetMark Inc's portfolio in Q3 2026, its #2223 holding.
  • AssetMark Inc first reported a position in Fulcrum Therapeutics in Q3 2025 and has held it in 5 quarters since.
  • AssetMark Inc's Fulcrum Therapeutics position peaked at $92.6K in Q4 2025.
  • 42 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q3 2026.

Based on AssetMark Inc's 13F filing for Q3 2026, filed 21 Oct 2026.